



**Q1 2024 Supplemental Financial Information**

## Table of Contents

<a href="#"><u>Non-GAAP Financial Measures</u></a>	<a href="#"><u>1</u></a>
<a href="#"><u>Condensed Consolidated Statements of Operations - Fiscal Quarters</u></a>	<a href="#"><u>2</u></a>
<a href="#"><u>Condensed Consolidated Balance Sheets</u></a>	<a href="#"><u>3</u></a>
<a href="#"><u>Condensed Consolidated Statements of Cash Flows - Fiscal Quarters</u></a>	<a href="#"><u>4</u></a>
<a href="#"><u>Reconciliation of GAAP to Non-GAAP Measures - Fiscal Quarters</u></a>	<a href="#"><u>5</u></a>
<a href="#"><u>Remaining Performance Obligations</u></a>	<a href="#"><u>8</u></a>

## **Non-GAAP Financial Measures**

This supplemental financial information contains financial statements that have not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). We use these non-GAAP financial measures and other key metrics internally to facilitate analysis of our financial and business trends and for internal planning and forecasting purposes. We believe these non-GAAP financial measures, when taken collectively, may be helpful to investors because they provide consistency and comparability with past financial performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. However, non-GAAP financial measures have limitations as an analytical tool and are presented for supplemental informational purposes only. They should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP.

A reconciliation of our non-GAAP financial measures to the most directly comparable GAAP measures has been provided in the financial statement tables included in this supplemental financial information, and investors are encouraged to review these reconciliations.

**Confluent, Inc.**  
**Condensed Consolidated Statements of Operations - Fiscal Quarters**  
*(in thousands, except percentages, share and per share data)*  
*(unaudited)*

	Three Months Ended							
	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24
Revenue:								
Subscription	\$ 127,018	\$ 138,730	\$ 155,341	\$ 160,567	\$ 176,488	\$ 189,270	\$ 202,787	\$ 206,902
Services	12,389	13,002	13,325	13,735	12,797	10,911	10,397	10,335
Total revenue	139,407	151,732	168,666	174,302	189,285	200,181	213,184	217,237
Cost of revenue:								
Subscription	35,608	38,417	38,696	42,905	44,188	44,104	44,807	48,355
Services	13,901	14,763	15,253	15,239	13,732	12,445	12,250	12,866
Total cost of revenue	49,509	53,180	53,949	58,144	57,920	56,549	57,057	61,221
Gross profit	89,898	98,552	114,717	116,158	131,365	143,632	156,127	156,016
Subscription	72.0%	72.3%	75.1%	73.3%	75.0%	76.7%	77.9%	76.6%
Services	(12.2%)	(13.5%)	(14.5%)	(11.0%)	(7.3%)	(14.1%)	(17.8%)	(24.5%)
Total gross margin	64.5%	65.0%	68.0%	66.6%	69.4%	71.8%	73.2%	71.8%
Operating expenses:								
Research and development	64,472	70,099	71,809	84,890	85,677	91,237	86,948	97,571
Sales and marketing	112,754	114,312	122,684	128,624	127,770	128,624	119,911	131,352
General and administrative	29,979	33,041	35,209	35,355	36,343	31,874	33,948	38,444
Restructuring and other related charges	-	-	-	33,382	943	529	-	-
Total operating expenses	207,205	217,452	229,702	282,251	250,733	252,264	240,807	267,367
Operating loss	(117,307)	(118,900)	(114,985)	(166,093)	(119,368)	(108,632)	(84,680)	(111,351)
Other income, net	1,186	4,719	11,327	15,185	17,610	17,529	21,775	20,850
Loss before income taxes	(116,121)	(114,181)	(103,658)	(150,908)	(101,758)	(91,103)	(62,905)	(90,501)
Provision for income taxes	1,510	1,868	2,226	1,647	1,667	1,567	31,191	2,466
Net loss	\$ (117,631)	\$ (116,049)	\$ (105,884)	\$ (152,555)	\$ (103,425)	\$ (92,670)	\$ (94,096)	\$ (92,967)
Net loss per share, basic and diluted	\$ (0.42)	\$ (0.41)	\$ (0.37)	\$ (0.52)	\$ (0.35)	\$ (0.30)	\$ (0.30)	\$ (0.30)
Weighted-average shares used to compute net loss per share, basic and diluted	278,268,980	282,267,230	286,732,756	291,864,975	297,827,200	303,896,632	309,101,119	314,203,181

**Confluent, Inc.**  
**Condensed Consolidated Balance Sheets**  
*(in thousands)*  
*(unaudited)*

	March 31, 2024	December 31, 2023
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 336,373	\$ 349,761
Marketable securities	1,570,586	1,551,009
Accounts receivable, net	199,842	229,962
Deferred contract acquisition costs	43,214	43,937
Prepaid expenses and other current assets	76,102	76,986
Total current assets	2,226,117	2,251,655
Property and equipment, net	61,627	54,012
Operating lease right-of-use assets	9,176	10,061
Goodwill and intangible assets, net	54,988	55,490
Deferred contract acquisition costs, non-current	73,508	75,815
Other assets, non-current	14,213	13,776
Total assets	\$ 2,439,629	\$ 2,460,809
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,882	\$ 6,714
Accrued expenses and other liabilities	96,739	141,847
Operating lease liabilities	10,061	7,890
Deferred revenue	330,516	330,570
Total current liabilities	439,198	487,021
Operating lease liabilities, non-current	13,284	17,391
Deferred revenue, non-current	17,145	22,436
Convertible senior notes, net	1,089,266	1,088,313
Other liabilities, non-current	35,519	35,233
Total liabilities	1,594,412	1,650,394
Stockholders' equity:		
Preferred stock	-	-
Class A common stock	2	2
Class B common stock	1	1
Additional paid-in capital	2,584,665	2,453,293
Accumulated other comprehensive (loss) income	(2,333)	1,270
Accumulated deficit	(1,737,118)	(1,644,151)
Total stockholders' equity	845,217	810,415
Total liabilities and stockholders' equity	\$ 2,439,629	\$ 2,460,809

**Confluent, Inc.**  
**Condensed Consolidated Statements of Cash Flows - Fiscal Quarters**  
*(in thousands)*  
*(unaudited)*

	Three Months Ended							
	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>								
Net loss	\$ (117,631)	\$ (116,049)	\$ (105,884)	\$ (152,555)	\$ (103,425)	\$ (92,670)	\$ (94,096)	\$ (92,967)
Adjustments to reconcile net loss to cash (used in) provided by operating activities:								
Depreciation and amortization	1,810	2,075	2,485	3,122	3,256	3,609	3,923	4,311
Net accretion of discounts on marketable securities	(469)	(3,105)	(6,022)	(9,133)	(10,588)	(11,300)	(11,484)	(10,396)
Amortization of debt issuance costs	947	958	959	939	950	961	963	953
Amortization of deferred contract acquisition costs	8,925	9,658	10,286	10,484	11,053	11,923	12,428	12,762
Non-cash operating lease costs	2,200	2,142	1,991	1,207	977	934	874	885
Lease abandonment charges	-	-	-	15,667	-	-	-	-
Stock-based compensation, net of amounts capitalized	68,866	75,393	76,028	79,289	92,159	89,514	88,871	95,322
Deferred income taxes	30	20	(283)	5	5	15	1,864	615
Other	355	321	504	279	572	2,263	(756)	849
Changes in operating assets and liabilities, net of effects of business combinations:								
Accounts receivable	(25,244)	6,047	(35,665)	8,068	(19,361)	5,153	(47,453)	29,360
Deferred contract acquisition costs	(10,643)	(19,354)	(20,724)	(10,160)	(13,806)	(15,607)	(21,781)	(9,732)
Prepaid expenses and other assets	(12,136)	(977)	3,248	3,141	(9,198)	(7,768)	3,438	(1,929)
Accounts payable	7,275	(1,004)	7,132	(11,325)	(7,395)	(488)	4,756	(4,932)
Accrued expenses and other liabilities	24,609	(35)	8,226	(16,557)	24,109	10,413	43,368	(43,752)
Operating lease liabilities	(2,413)	(2,029)	(2,270)	(1,998)	(1,756)	(1,808)	(1,917)	(1,935)
Deferred revenue	20,047	4,187	32,911	1,755	3,388	(4,204)	29,237	(5,368)
Net cash (used in) provided by operating activities	(33,472)	(41,752)	(27,078)	(77,772)	(29,060)	(9,060)	12,235	(25,954)
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>								
Capitalization of internal-use software costs	(2,256)	(2,788)	(2,781)	(4,556)	(5,330)	(3,660)	(4,299)	(5,539)
Purchases of marketable securities	(763,479)	(355,886)	(528,660)	(453,356)	(546,408)	(235,824)	(351,105)	(443,307)
Maturities of marketable securities	275,114	347,000	482,899	451,777	523,606	228,328	374,612	432,267
Purchases of property and equipment	(1,184)	(1,044)	(1,006)	(546)	(809)	(363)	(1,116)	(186)
Cash paid for business combinations, net of cash acquired	-	-	-	(45,802)	-	-	(10,000)	-
Net cash (used in) provided by investing activities	(491,805)	(12,718)	(49,548)	(52,483)	(28,941)	(11,519)	8,092	(16,765)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>								
Proceeds from issuance of common stock upon exercise of vested options	7,947	9,749	8,329	20,780	27,492	14,673	10,974	14,401
Proceeds from issuance of common stock upon early exercise of unvested options	71	-	-	-	-	-	-	-
Repurchases of unvested common stock and options	(683)	(14)	(80)	(223)	-	(32)	-	-
Proceeds from issuance of common stock under employee stock purchase plan	-	18,454	-	17,172	-	11,536	-	15,603
Net cash provided by financing activities	7,335	28,189	8,249	37,729	27,492	26,177	10,974	30,004
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	20	20	2	205	(308)	(1,198)	1,417	(673)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(517,922)	(26,261)	(68,375)	(92,321)	(30,817)	4,400	32,718	(13,388)
Cash, cash equivalents, and restricted cash at beginning of period	1,048,339	530,417	504,156	435,781	343,460	312,643	317,043	349,761
Cash, cash equivalents, and restricted cash at end of period	\$ 530,417	\$ 504,156	\$ 435,781	\$ 343,460	\$ 312,643	\$ 317,043	\$ 349,761	\$ 336,373
<b>Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets to the amounts shown above:</b>								
Cash and cash equivalents	\$ 529,667	\$ 503,406	\$ 435,781	\$ 343,460	\$ 312,643	\$ 317,043	\$ 349,761	\$ 336,373
Restricted cash included in other assets, current	750	750	-	-	-	-	-	-
Total cash, cash equivalents, and restricted cash	\$ 530,417	\$ 504,156	\$ 435,781	\$ 343,460	\$ 312,643	\$ 317,043	\$ 349,761	\$ 336,373

**Confluent, Inc.**  
**Reconciliation of GAAP to Non-GAAP Measures - Fiscal Quarters**  
*(in thousands, except percentages, share and per share data)*  
*(unaudited)*

	Three Months Ended							
	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24
<b>Reconciliation of GAAP total gross profit to non-GAAP total gross profit:</b>								
Total gross profit on a GAAP basis	\$ 89,898	\$ 98,552	\$ 114,717	\$ 116,158	\$ 131,365	\$ 143,632	\$ 156,127	\$ 156,016
<i>Total gross margin on a GAAP basis</i>	64.5%	65.0%	68.0%	66.6%	69.4%	71.8%	73.2%	71.8%
Add: Stock-based compensation-related charges <sup>(1)</sup>	8,496	9,141	8,340	9,516	10,432	9,095	8,932	10,623
Add: Amortization of acquired intangibles	-	-	-	113	127	129	195	502
Non-GAAP total gross profit	<u>\$ 98,394</u>	<u>\$ 107,693</u>	<u>\$ 123,057</u>	<u>\$ 125,787</u>	<u>\$ 141,924</u>	<u>\$ 152,856</u>	<u>\$ 165,254</u>	<u>\$ 167,141</u>
<i>Non-GAAP total gross margin</i>	70.6%	71.0%	73.0%	72.2%	75.0%	76.4%	77.5%	76.9%
<b>Reconciliation of GAAP subscription gross profit to non-GAAP subscription gross profit:</b>								
Subscription gross profit on a GAAP basis	\$ 91,410	\$ 100,313	\$ 116,645	\$ 117,662	\$ 132,300	\$ 145,166	\$ 157,980	\$ 158,547
<i>Subscription gross margin on a GAAP basis</i>	72.0%	72.3%	75.1%	73.3%	75.0%	76.7%	77.9%	76.6%
Add: Stock-based compensation-related charges <sup>(1)</sup>	6,088	6,395	5,576	6,649	7,179	6,350	6,309	7,905
Add: Amortization of acquired intangibles	-	-	-	113	127	129	195	502
Non-GAAP subscription gross profit	<u>\$ 97,498</u>	<u>\$ 106,708</u>	<u>\$ 122,221</u>	<u>\$ 124,424</u>	<u>\$ 139,606</u>	<u>\$ 151,645</u>	<u>\$ 164,484</u>	<u>\$ 166,954</u>
<i>Non-GAAP subscription gross margin</i>	76.8%	76.9%	78.7%	77.5%	79.1%	80.1%	81.1%	80.7%

	Three Months Ended							
	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24
<b>Reconciliation of GAAP operating expenses to non-GAAP operating expenses:</b>								
Research and development operating expense on a GAAP basis	\$ 64,472	\$ 70,099	\$ 71,809	\$ 84,890	\$ 85,677	\$ 91,237	\$ 86,948	\$ 97,571
<i>Research and development operating expense as a percentage of total revenue on a GAAP basis</i>	46.2%	46.2%	42.6%	48.7%	45.3%	45.6%	40.8%	44.9%
Less: Stock-based compensation-related charges <sup>(1)</sup>	25,679	28,188	29,140	31,684	36,726	38,464	36,972	41,424
Less: Acquisition-related expenses	-	-	-	7,680	3,841	3,841	3,841	4,362
Non-GAAP research and development operating expense	\$ 38,793	\$ 41,911	\$ 42,669	\$ 45,526	\$ 45,110	\$ 48,932	\$ 46,135	\$ 51,785
<i>Non-GAAP research and development operating expense as a percentage of total revenue</i>	27.8%	27.6%	25.3%	26.1%	23.8%	24.4%	21.6%	23.8%
Sales and marketing operating expense on a GAAP basis	\$ 112,754	\$ 114,312	\$ 122,684	\$ 128,624	\$ 127,770	\$ 128,624	\$ 119,911	\$ 131,352
<i>Sales and marketing operating expense as a percentage of total revenue on a GAAP basis</i>	80.9%	75.3%	72.7%	73.8%	67.5%	64.3%	56.2%	60.5%
Less: Stock-based compensation-related charges <sup>(1)</sup>	25,794	27,292	27,023	29,570	34,377	33,095	31,406	35,780
Less: Acquisition-related expenses	-	-	-	1,076	1,076	1,076	1,076	-
Non-GAAP sales and marketing operating expense	\$ 86,960	\$ 87,020	\$ 95,661	\$ 97,978	\$ 92,317	\$ 94,453	\$ 87,429	\$ 95,572
<i>Non-GAAP sales and marketing operating expense as a percentage of total revenue</i>	62.4%	57.4%	56.7%	56.2%	48.8%	47.2%	41.0%	44.0%
General and administrative operating expense on a GAAP basis	\$ 29,979	\$ 33,041	\$ 35,209	\$ 35,355	\$ 36,343	\$ 31,874	\$ 33,948	\$ 38,444
<i>General and administrative operating expense as a percentage of total revenue on a GAAP basis</i>	21.5%	21.8%	20.9%	20.3%	19.2%	15.9%	15.9%	17.7%
Less: Stock-based compensation-related charges <sup>(1)</sup>	10,567	12,141	13,057	12,182	14,223	11,333	12,857	15,158
Less: Acquisition-related expenses	-	-	1,104	561	281	148	650	225
Non-GAAP general and administrative operating expense	\$ 19,412	\$ 20,900	\$ 21,048	\$ 22,612	\$ 21,839	\$ 20,393	\$ 20,441	\$ 23,061
<i>Non-GAAP general and administrative operating expense as a percentage of total revenue</i>	13.9%	13.8%	12.5%	13.0%	11.5%	10.2%	9.6%	10.6%



	Three Months Ended							
	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24
<b>Reconciliation of GAAP operating loss to non-GAAP operating (loss) income:</b>								
Operating loss on a GAAP basis	\$ (117,307)	\$ (118,900)	\$ (114,985)	\$ (166,093)	\$ (119,368)	\$ (108,632)	\$ (84,680)	\$ (111,351)
<i>GAAP operating margin</i>	<i>(84.1%)</i>	<i>(78.4%)</i>	<i>(68.2%)</i>	<i>(95.3%)</i>	<i>(63.1%)</i>	<i>(54.3%)</i>	<i>(39.7%)</i>	<i>(51.3%)</i>
Add: Stock-based compensation-related charges <sup>(1)</sup>	70,536	76,762	77,560	82,952	95,758	91,987	90,167	102,985
Add: Amortization of acquired intangibles	-	-	-	113	127	129	195	502
Add: Acquisition-related expenses	-	-	1,104	9,317	5,198	5,065	5,567	4,587
Add: Restructuring and other related charges	-	-	-	33,382	943	529	-	-
Non-GAAP operating (loss) income	<u>\$ (46,771)</u>	<u>\$ (42,138)</u>	<u>\$ (36,321)</u>	<u>\$ (40,329)</u>	<u>\$ (17,342)</u>	<u>\$ (10,922)</u>	<u>\$ 11,249</u>	<u>\$ (3,277)</u>
<i>Non-GAAP operating margin</i>	<i>(33.5%)</i>	<i>(27.8%)</i>	<i>(21.5%)</i>	<i>(23.1%)</i>	<i>(9.2%)</i>	<i>(5.5%)</i>	<i>5.3%</i>	<i>(1.5%)</i>
<b>Reconciliation of GAAP net loss to non-GAAP net (loss) income:</b>								
Net loss on a GAAP basis	\$ (117,631)	\$ (116,049)	\$ (105,884)	\$ (152,555)	\$ (103,425)	\$ (92,670)	\$ (94,096)	\$ (92,967)
Add: Stock-based compensation-related charges <sup>(1)</sup>	70,536	76,762	77,560	82,952	95,758	91,987	90,167	102,985
Add: Amortization of acquired intangibles	-	-	-	113	127	129	195	502
Add: Acquisition-related expenses	-	-	1,104	9,317	5,198	5,065	5,567	4,587
Add: Restructuring and other related charges	-	-	-	33,382	943	529	-	-
Add: Amortization of debt issuance costs	946	958	959	939	950	961	963	953
Add: Income tax effects and adjustments <sup>(2)</sup>	669	293	656	362	507	328	29,373	(260)
Non-GAAP net (loss) income	<u>\$ (45,480)</u>	<u>\$ (38,036)</u>	<u>\$ (25,605)</u>	<u>\$ (25,490)</u>	<u>\$ 58</u>	<u>\$ 6,329</u>	<u>\$ 32,169</u>	<u>\$ 15,800</u>
Non-GAAP net (loss) income per share, basic	<u>\$ (0.16)</u>	<u>\$ (0.13)</u>	<u>\$ (0.09)</u>	<u>\$ (0.09)</u>	<u>\$ 0.00</u>	<u>\$ 0.02</u>	<u>\$ 0.10</u>	<u>\$ 0.05</u>
Non-GAAP net (loss) income per share, diluted	<u>\$ (0.16)</u>	<u>\$ (0.13)</u>	<u>\$ (0.09)</u>	<u>\$ (0.09)</u>	<u>\$ 0.00</u>	<u>\$ 0.02</u>	<u>\$ 0.09</u>	<u>\$ 0.05</u>
Weighted-average shares used to compute non-GAAP net (loss) income per share, basic	<u>278,268,980</u>	<u>282,267,230</u>	<u>286,732,756</u>	<u>291,864,975</u>	<u>297,827,200</u>	<u>303,896,632</u>	<u>309,101,119</u>	<u>314,203,181</u>
Weighted-average shares used to compute non-GAAP net (loss) income per share, diluted	<u>278,268,980</u>	<u>282,267,230</u>	<u>286,732,756</u>	<u>291,864,975</u>	<u>339,296,142</u>	<u>346,974,638</u>	<u>342,370,878</u>	<u>350,195,868</u>

<sup>(1)</sup> Represents stock-based compensation expense, employer taxes on employee stock transactions, and amortization of stock-based compensation capitalized in internal-use software. We began excluding amortization of stock-based compensation capitalized in internal-use software from our non-GAAP measures starting with the quarter ended March 31, 2024. The amounts of amortization of stock-based compensation capitalized in internal-use software were immaterial in both current and prior periods.

<sup>(2)</sup> Income tax effects and adjustments for the three months ended December 31, 2023 primarily consists of income tax expense related to an intra-group transfer of acquired intellectual property.

	Three Months Ended								
	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	
Net cash (used in) provided by operating activities	\$ (33,472)	\$ (41,752)	\$ (27,078)	\$ (77,772)	\$ (29,060)	\$ (9,060)	\$ 12,235	\$ (25,954)	
Capitalized internal-use software costs	(2,256)	(2,788)	(2,781)	(4,556)	(5,330)	(3,660)	(4,299)	(5,539)	
Capital expenditures	(1,184)	(1,044)	(1,006)	(546)	(809)	(363)	(1,116)	(186)	
Free cash flow	\$ (36,912)	\$ (45,584)	\$ (30,865)	\$ (82,874)	\$ (35,199)	\$ (13,083)	\$ 6,820	\$ (31,679)	
<i>Free cash flow margin</i>	<i>(26.5%)</i>	<i>(30.0%)</i>	<i>(18.3%)</i>	<i>(47.5%)</i>	<i>(18.6%)</i>	<i>(6.5%)</i>	<i>3.2%</i>	<i>(14.6%)</i>	
Net cash (used in) provided by investing activities	\$ (491,805)	\$ (12,718)	\$ (49,548)	\$ (52,483)	\$ (28,941)	\$ (11,519)	\$ 8,092	\$ (16,765)	
Net cash provided by financing activities	\$ 7,335	\$ 28,189	\$ 8,249	\$ 37,729	\$ 27,492	\$ 26,177	\$ 10,974	\$ 30,004	

### Remaining Performance Obligations (“RPO”)

RPO represent the amount of contracted future revenue that has not yet been recognized as of the end of each period, including both deferred revenue that has been invoiced and non-cancelable committed amounts that will be invoiced and recognized as revenue in future periods. RPO exclude pay-as-you-go arrangements. As of March 31, 2024, the Company’s RPO was \$840.2 million, approximately 68% of which is expected to be recognized as revenue over the next 12 months and the substantial majority of the remainder in the next 13 to 36 months. Actual amounts or timing of revenue recognized may differ due to subsequent contract modifications.